文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症呼吸衰竭与机械通气

危重症COVID-19与非COVID-19急性呼吸系统疾病队列中重度急性肾损伤的生物标志物特征

Biomarker Signatures of Severe Acute Kidney Injury in a Critically Ill Cohort of COVID-19 and Non-COVID-19 Acute Respiratory Illness.
PubMed 文献 · Crit Care Explor · 2023-07-13
一句话结论在ICU急性呼吸系统疾病患者中,sTNFR-1与sTREM-1升高与重度AKI风险独立相关,而sPDL-1、sICAM-1、sVCAM-1与重度AKI和重度ARF均相关。

该前瞻性观察性队列研究于2020年3月至2021年5月在大型学术医疗系统的三家医院纳入301例因急性呼吸系统疾病入住ICU的患者,在入ICU 24小时内检测血浆免疫反应与内皮功能相关生物标志物。主要结局为入ICU至第14天内的重度AKI(血清肌酐翻倍或新开始透析)和重度ARF(新出现或持续需要高流量氧疗或机械通气)。48例(16%)发生重度AKI,147例(49%)发生重度ARF,40例(13%)两者均发生。校正年龄、性别、COVID-19和APACHE-III后,sTNFR-1每升高两倍与重度AKI风险相关(aRR 1.56;95%CI 1.24-1.96),sTREM-1每升高两倍与重度AKI风险相关(aRR 1.85;95%CI 1.42-2.41),两者与重度ARF无显著关联;sPDL-1、sICAM-1和sVCAM-1与重度AKI和ARF均相关。

要点

  • 入ICU 24小时内sTNFR-1每升高两倍,重度AKI风险aRR 1.56(95%CI 1.24-1.96),校正年龄、性别、COVID-19和APACHE-III。
  • 入ICU 24小时内sTREM-1每升高两倍,重度AKI风险aRR 1.85(95%CI 1.42-2.41),校正因素同上。
  • sTNFR-1和sTREM-1与重度ARF无显著关联;sPDL-1、sICAM-1、sVCAM-1与重度AKI和重度ARF均相关。
  • 队列中重度AKI 48例(16%)、重度ARF 147例(49%)、两者均发生40例(13%)。
  • 作者认为这些生物标志物特征可能揭示肺-肾相互作用的病理生理,并为识别高危器官损伤患者的精准医学策略提供信息。

适用人群与场景

  • 2020年3月至2021年5月在大型学术医疗系统三家医院因急性呼吸系统疾病入住ICU的301例患者,包括COVID-19与非COVID-19急性呼吸系统疾病。

诊断标准与关键阈值

  • 重度AKI:血清肌酐翻倍或新开始透析。
  • 重度ARF:新出现或持续需要高流量氧疗或机械通气。
  • 结局判定时间窗:入ICU至第14天。
  • 生物标志物检测:入ICU 24小时内采集的血浆。

研究设计与关键结果

  • 前瞻性观察性队列研究,纳入301例因急性呼吸系统疾病入住ICU的患者,来自大型学术医疗系统的三家医院,入组时间2020年3月至2021年5月。
  • 主要结局:入ICU至第14天内重度AKI 48例(16%)、重度ARF 147例(49%)、两者均发生40例(13%)。
  • 在校正年龄、性别、COVID-19和APACHE-III后,sTNFR-1每升高两倍与重度AKI风险相关(aRR 1.56;95%CI 1.24-1.96),sTREM-1每升高两倍与重度AKI风险相关(aRR 1.85;95%CI 1.42-2.41)。
  • sTNFR-1和sTREM-1与重度ARF无显著关联。
  • sPDL-1、sICAM-1和sVCAM-1与重度AKI和重度ARF均相关。

证据类型、等级与局限

  • 证据类型:前瞻性观察性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为sTNFR-1和sTREM-1与呼吸系统疾病期间重度AKI强相关,sPDL-1、sICAM-1和sVCAM-1与重度AKI和ARF均相关,这些生物标志物特征可能为识别高危器官损伤患者的精准医学策略提供信息。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

UNLABELLED: Kidney and lung injury are closely inter-related during acute respiratory illness, but the molecular risk factors that these organ injuries share are not well defined.

OBJECTIVES: We identified plasma biomarkers associated with severe acute kidney injury (AKI) during acute respiratory illness, and compared them to biomarkers associated with severe acute respiratory failure (ARF).

DESIGN SETTINGS AND PARTICIPANTS: Prospective observational cohort study enrolling March 2020 through May 2021, at three hospitals in a large academic health system. We analyzed 301 patients admitted to an ICU with acute respiratory illness.

MAIN OUTCOMES AND MEASURES: Outcomes were ascertained between ICU admission and day 14, and included: 1) severe AKI, defined as doubling of serum creatinine or new dialysis and 2) severe ARF, which included new or persistent need for high-flow oxygen or mechanical ventilation. We measured biomarkers of immune response and endothelial function, pathways related to adverse kidney and lung outcomes, in plasma collected within 24 hours of ICU admission. Severe AKI occurred in 48 (16%), severe ARF occurred in 147 (49%), and 40 (13%) patients experienced both. Two-fold higher concentrations of soluble tumor necrosis factor receptor-1 (sTNFR-1) (adjusted relative risk [aRR], 1.56; 95% CI, 1.24-1.96) and soluble triggering receptor on myeloid cells-1 (sTREM-1) (aRR, 1.85; 95% CI, 1.42-2.41), biomarkers of innate immune activation, were associated with higher risk for severe AKI after adjustment for age, sex, COVID-19, and Acute Physiology and Chronic Health Evaluation-III. These biomarkers were not significantly associated with severe ARF. Soluble programmed cell death receptor-1 (sPDL-1), a checkpoint pathway molecule, as well as soluble intercellular adhesion molecule-1 (sICAM-1) and soluble vascular adhesion molecule-1 (sVCAM-1), molecules involved with endothelial-vascular leukocyte adhesion, were associated with both severe AKI and ARF.

CONCLUSIONS AND RELEVANCE: sTNFR-1 and sTREM-1 were linked strongly to severe AKI during respiratory illness, while sPDL-1, sICAM-1 and sVCAM-1 were associated with both severe AKI and ARF. These biomarker signatures may shed light on pathophysiology of lung-kidney interactions, and inform precision medicine strategies for identifying patients at high risk for these organ injuries.

来源:Crit Care Explor,查看原文。版权归原作者所有。

参考来源

  1. Sathe NA, Mostaghim A, Barnes E, et al. Biomarker Signatures of Severe Acute Kidney Injury in a Critically Ill Cohort of COVID-19 and Non-COVID-19 Acute Respiratory Illness. Crit Care Explor. 2023. PMID: 37457915. doi:10.1097/CCE.0000000000000945

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。